Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
Search Article 
Advanced search 
  Users Online: 357 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

    Article Cited by others


Dyslipidemic drugs in metabolic syndrome

Siddiqi Sheelu S, Misbahuddin, Ahmad Farida, Rahman Syed Z, Khan Asad U

Year : 2013| Volume: 17| Issue : 3 | Page no: 472-479

   This article has been cited by
1 Comparative evaluation of clinical and inflammatory factors in response to the pharmacological managements in metabolic syndrome
Arpit Jain,Suraj S. Yadav,Pradeep Dwivedi,Devendra K. Katiyar,Kauser Usman,Sanjay Khattri
International Journal of Diabetes in Developing Countries. 2016;
[Pubmed]  [Google Scholar] [DOI]
2 Effect of an SNP in SCAP gene on lipid-lowering response to rosuvastatin in Indian patients with metabolic syndrome
Misbahuddin M Rafeeq,Farida Ahmad,Syed Z Rahman,Sheelu S Siddiqi,Shazi Shakil
Pharmacogenomics. 2016; 17(18): 2015
[Pubmed]  [Google Scholar] [DOI]
3 Rosuvastatin for lowering lipids
Stephen P Adams,Sarpreet S Sekhon,James M Wright
Cochrane Database of Systematic Reviews. 2014;
[Pubmed]  [Google Scholar] [DOI]
4 Comparison of Cost-Effectiveness, Safety, and Efficacy of Rosuvastatin Versus Atorvastatin, Pravastatin, and Simvastatin in Dyslipidemic Diabetic Patients With or Without Metabolic Syndrome
Abdulbari Bener,Muzeyyen Dogan,Lolwa Barakat,Abdulla O. A. A. Al-Hamaq
Journal of Primary Care & Community Health. 2014; 5(3): 180
[Pubmed]  [Google Scholar] [DOI]


Read this article